Vertex Pharma (VRTX) Tops Q1 EPS by 68c; reiterates guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $528.04 +6.03%
EPS Growth %: +4.4%
Financial Fact:
Loss from operations: -18.73M
Today's EPS Names:
CRMT, More
EPS Growth %: +4.4%
Financial Fact:
Loss from operations: -18.73M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $4.76, $0.68 better than the analyst estimate of $4.08. Revenue for the quarter came in at $2.69 billion versus the consensus estimate of $2.58 billion.
GUIDANCE:
Vertex Pharma sees FY2024 revenue of $10.55-10.75 billion, versus the consensus of $10.718 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Lindsay (LNN) Tops Q3 EPS by 18c, Misses on Revenue
- Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
